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WHOLE EXOME SEQUENCING IDENTIFIES NOVEL MUTATIONS IN 
RELAPSED OR REFRACTORY ACUTE PROMYELOCYTIC LEUKAEMIA 
FAILING TREATMENT WITH ORAL ARSENIC TRIOXIDE 
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BACKGROUND 
Arsenic trioxide (As2O3)-based regimens is effective in inducing a remission in more than 90 
percent of relapsed acute promyelocytic leukaemia (APL). Treatment failure following As2O3 
and central nervous system (CNS) involvement is associated a poor prognosis. With the 
widespread clinical application of arsenic trioxide in the frontline and relapsed setting, arsenic 
trioxide resistance is an emerging clinical problem. There is paucity of information of the 
molecular mechanisms underlying resistance to As2O3. 
 
AIMS 
To determine mutations associated with resistance to oral As2O3 in relapsed or refractory APL 
using serial whole exome sequencing.  
 
METHODS 
DNA was extracted from the buffy coat in serially archived bone marrow (BM) samples of 7 
patients with 2 or more relapses following treatment with oral As2O3. Paired BM samples 
(As2O3-resistant sample was paired with the corresponding As2O3-sensitive sample from the 
same patient) were evaluated with whole exome sequencing (WES) using the illumina HiSeq 
1500 platform with an average depth of 100X. The exome data was analysed using 
bio-informatic pipeline specifically designed to identify single nucleotide variants (SNVs) 
with increased allele frequency during oral As2O3 failure. The functional influences of 
nonsynonymous missense mutations are evaluated using SIFT, Polyphen2 and FATHMM. To 
confirm putative SNVs in these samples, re-sequencing by Sanger sequencing was performed 
using DNA submitted for exome sequencing. The confirmed SNVs were evaluated in the 
entire validation cohort of 22 patients with relapsed or refractory APL following oral 
As2O3-based treatment. Clinicopathologic features, karyotype, FLT3 and PML-RARA 
mutations were determined in all patients with relapsed or refractory APL. 
 
RESULTS 
By serial WES in 7 patients with APL refractory to oral As2O3-based treatment, the following 
SNVs of function-changing potential had increased allele frequency and during treatment 
resistance: NOTCH2, FOXD4L5, KCNJ11/18, MADCAL1, CBR3, NSD1, FLG1, CCCDC179, 
SIGLEC11, ROBO4, CISD2, WT1, PTCH1, KMT2D and MED17. PML B2 domain mutations 
were not seen. These putative SNVs were all confirmed positive by Sanger sequencing. The 
frequencies of the mutations were validated in a cohort of 22 patients with relapsed or 
refractory APL following oral As2O3-based treatment. The recruited patients comprised 14 
men and 8 women with a median age of 44.5 (range:24-76) years at relapse. 1 (5%) patient 
had microgranular variant of APL while 2 patients (9%) had therapy-related APL. Additional 
karyotypic abnormalities were seen in 3 (14%) patients.14 patients (64%) had central nervous 
system (CNS) involvement at relapse. Internal tandem duplication of FLT3 (FLT3-ITD) was 
detected in 7 (32%) patients. The following recurrent mutations were found: NOTCH2 (n=17, 
77%), FOXD4L5 (n=22, 100%), KCNJ11/18 (n=14, 64%), MADCAM1 (n=15, 68%), CBR3 
(n=17, 77%), NSD1 (n=17, 77%), FLG1 (n=20, 91%), CCCDC179 (n=7, 32%), SIGLEC11 
(n=5, 23%), ROBO4 (n=3, 14%), CISD2 (n=3, 14%), WT1 (n=1, 5%), PTCH1(n=1, 5%), 
KMT2D (n=1, 5%) and MED17 (n=6, 27%).  
 
CONCLUSIONS 
Mechanisms other than PML B2 domain mutations may account for As2O3 resistance. Novel 
genes regulating the apoptotic pathways, cellular proliferation, histone modification, DNA 
repair and angiogenesis were frequently mutated in As2O3-refractory APL. Further functional 
validation on the role of these mutations in conferring As2O3 resistance is required.  
